biostudies-literatureUnknown46(11)Debonnaire PBristol-Myers SquibbTakeda PharmaceuticalsSwedish Orphan Biovitrum ABPfizerBoehringer Ingelheim<h4>Background and aims</h4>In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied.<h4>Methods</h4>An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed.<h4>Results</h4>The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural cEuropean heart journal1057-1070https://www.ebi.ac.uk/biostudies/studies/S-EPMC11905754biostudies-literatureTafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.PMC11905754Buytaert LZach DKTavernier RBohyn AClaeys MBuysschaert IDroogmans SEl Haddad MVan Hoeyweghen RTrenson SDujardin KJacobs ABogaerts KChristiaen EVerheyen NDebonnaire PPouleur ACWyseure NfalseTafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.<h4>Background and aims</h4>In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied.<h4>Methods</h4>An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed.<h4>Results</h4>The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural c2025-01-01T00:00:00Z2025 Mar2025-04-04T00:31:51.177Z2025-04-04T00:31:51.177ZS-EPMC119057544003620210.1093/eurheartj/ehae923